Biomea Fusion Rises 11% as Analysts Show Optimism After FDA Removes Clinical Holds on BMF-219 for Type 2 and Type 1 Diabetes Trials

Biomea Fusion, Inc. (BMEA) experienced an 11% increase in shares following positive feedback from analysts after the FDA removed its clinical holds on BMF-219 for trials related to Type 1 and Type 2 diabetes. Additionally, Truist and Rodman and Renshaw have upgraded their ratings for the company.